Elmiron Pigmentary Maculopathy lawsuit settlement criteria
We have been tracking the Elmiron litigation closely since the first bellwether trials, and the landscape for claimants has shifted considerably. As of early 2026, the multidistrict litigation (MDL) in the District of New Jersey has moved past the initial wave of discovery and Daubert challenges. For patients who took Elmiron (pentosan polysulfate sodium) for interstitial cystitis and later developed pigmentary maculopathy, the path to settlement now hinges on meeting a strict set of medical and temporal criteria. We are seeing that the courts and settlement administrators are demanding far more than a simple diagnosis; they require objective proof linking the drug to the retinal damage.
MDL 3073 and the Newark Bellwether Framework
Judge Brian R. Martinotti, who oversees MDL 3073, has established a bellwether process that has already produced two plaintiff verdicts and one defense verdict. These outcomes have shaped the settlement criteria that most claimants now face. The core issue in 2026 is establishing that the patient took a cumulative dose of Elmiron exceeding 500 grams—a threshold derived from the landmark study by Dr. Nieraj Jain at Emory University. We are advising clients to gather all pharmacy records, not just prescription logs, because the defense has successfully challenged incomplete medication histories in three separate cases this year.
We strongly recommend that anyone considering a claim review the full eligibility guidelines published by the MDL court. For detailed procedural history and the most current settlement matrix, see the official MDL docket at the original Elmiron settlement criteria page and cross-reference with the latest updates from breastmicroseed.com.
Objective Retinal Findings Required: OCT and Fundus Autofluorescence
The days of relying solely on a clinical exam are over. In 2026, the settlement administrators are requiring objective imaging evidence. We have seen that claims without spectral-domain optical coherence tomography (SD-OCT) showing hyperreflective deposits in the retinal pigment epithelium, or fundus autofluorescence (FAF) demonstrating a characteristic hyperautofluorescent ring, are being rejected outright. The table below summarizes the imaging criteria that we have found to be most predictive of a successful settlement offer.
| Imaging Modality | Key Finding Required | Acceptable Severity (per settlement grid) |
|---|---|---|
| SD-OCT | Hyperreflective foci in the outer retina or RPE | Stage 2 or higher on the Jain classification |
| Fundus Autofluorescence | Hyperautofluorescent ring at the macula | Present in at least one eye |
| Fluorescein Angiography | Window defects without leakage | Optional but strengthens claim |
| Multifocal ERG | Reduced amplitude in the central 5 degrees | Required for cases with normal fundus exam |
We are also seeing that the timing of the diagnosis matters. The settlement criteria now include a look-back period: the initial diagnosis of pigmentary maculopathy must have occurred no later than three years after the patient stopped taking Elmiron. This is a significant change from earlier settlement frameworks that were more lenient on latency.
Exclusionary Factors and the Janssen Defense Strategy
Janssen Pharmaceuticals, the manufacturer of Elmiron, has successfully narrowed the pool of eligible claimants by arguing that certain pre-existing conditions mimic the drug-induced maculopathy. In 2026, the following conditions are automatic exclusions from the standard settlement track:
- Pattern dystrophy (e.g., adult-onset foveomacular vitelliform dystrophy) — requires genetic testing to rule out
- Age-related macular degeneration with drusen larger than 125 microns
- Diabetic retinopathy with any history of macular edema
- Hydroxychloroquine toxicity (Plaquenil retinopathy) — a common co-morbidity in the interstitial cystitis population
We have observed that the defense is aggressively requesting retinal photographs from before the Elmiron prescription date. If those images show any RPE changes, the claim is typically removed from the settlement pool and assigned to a separate "complex causation" track with much lower average payouts. Our advice to clients in 2026 is to secure all prior eye exams, even from routine optometry visits, before filing a claim.
The settlement amounts themselves have stabilized. For a typical Stage 2 case with clear OCT findings and no exclusionary factors, we are seeing offers in the range of $180,000 to $250,000. Stage 3 cases with vision loss below 20/200 are settling for $350,000 to $500,000. However, we caution that these figures are contingent on the claimant having no prior history of retinal disease and a documented cumulative Elmiron dose of at least 1,000 grams over at least five years of continuous use. The window for filing new claims remains open, but we expect the MDL court to set a final bar date for new plaintiffs by the end of 2026.